nderstanding the Psychological Impact, associated disorders and Treatment for Vitiligo

Not Applicable

• Conditions: Health Condition 1: L80- Vitiligo

• Registration Number: CTRI/2024/05/067554
• Lead Sponsor: Department of Dermatology Government Medical College Baramulla

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. All the patients diagnosed with Vitiligo of all age groups and of either sex visiting OPD of the Dermatology Department and who gave consent during the study period were included in this study.

2. Confirmed vitiligo diagnosis by a healthcare professional through clinical examination, dermoscopy, or biopsy (specific methodology may vary based on study design).

3. Consent to participate in the study procedures, including surveys, interviews, physical examinations, blood tests, or imaging studies (specific procedures depend on study focus).

4. No age or demographic restrictions unless studying specific populations (e.g., pregnant women, above 70 years).

5. Age of consent (e.g., 18+) and ability to complete psychological assessments.

6. Diagnosis of a specific co-occurring disorder confirmed through medical records or additional diagnostic procedures.

7. Specific disease type, severity, and age range suitable for the investigated treatment modality.

Exclusion Criteria

1. Patients not giving consent to participate in the study.

2. Mimicking Conditions: Presence of skin conditions that could mimic vitiligo (e.g., piebaldism, post-inflammatory hypopigmentation).

3. Self-Reported Vitiligo: Individuals lacking a professional diagnosis of vitiligo.

4. Cognitive/Psychiatric Conditions: Severe cognitive or psychiatric conditions that could significantly impact data collection or interpretation.

5. Medical Conditions: Presence of medical conditions that could confound study results or pose safety risks (e.g., chronic infections, certain medications).

6. Treatment Contraindications: Known contraindications to the specific treatment being investigated (e.g., allergies, specific medical conditions).

7. Ongoing Trials: Participation in other clinical trials that could interfere with study results.

8. Individuals with language barriers that impede effective communication may be excluded.

9. Pregnant or breastfeeding women may be excluded depending on the specific treatment safety data.

10. Uncertain diagnoses of vitiligo or co-occurring disorders may lead to exclusion to ensure study accuracy.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improved diagnosis and management strategies for healthcare professionals dealing with Vitiligo patients. <br/ ><br>Timepoint: 8 weeks <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
Enhanced psychological support and interventions to address the emotional and social impact of Vitiligo.Timepoint: 6 months;Evaluation of treatment options to determine their effectiveness, patient satisfaction, and areas for improvement. <br/ ><br>Timepoint: 6 months;Identification of potential Comorbidities and associated disorders to guide comprehensive patient care.Timepoint: 6 months